1:49 PM
 | 
Dec 02, 2016
 |  BC Week In Review  |  Company News  |  Deals

Abpro, AstraZeneca deal

The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 (ANG2; ANGPT2)...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >